TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24947583

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day (n = 26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy (n = 24)
Number of subjects: 50
Study: 22540534

Group type: EXPERIMENTAL
Intervention: In-person follow-up
Number of subjects: 245

Group type: COMPARATOR
Intervention: No in-person follow-up
Number of subjects: 245
Study: 19385713

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 for two 21-day cycles plus omeprazole 40 mg on days 6-10 and day 8 of cycle 1 or 2.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 for two 21-day cycles without omeprazole (control).
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bortezomib with omeprazole.
Number of subjects: 27
Study: 18459902

Group type: EXPERIMENTAL
Intervention: PET-guided stereotactic biopsy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PET-guided trajectories
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PET data
Number of subjects: 20
Study: 16236558

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure therapy (cognitive-behavioral therapy for PTSD)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Present-centered therapy (comparison treatment)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure therapy
Number of subjects: 384

Group type: COMPARATOR
Intervention: Present-centered therapy
Number of subjects: 384
Study: 11911726

Group type: EXPERIMENTAL
Intervention: Standardized telephonic case-management intervention for 6 months
Number of subjects: 358

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 358
Study: 9512881

Group type: EXPERIMENTAL
Intervention: Subjective eligibility criteria
Number of subjects: 224

Group type: COMPARATOR
Intervention: Objective eligibility criteria
Number of subjects: 224
Study: 7618707

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (standard transfusion therapy)
Number of subjects: 52
Study: 2096487

Group type: EXPERIMENTAL
Intervention: Subcutaneous DDAVP (0.3 microgram/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 361201

Group type: EXPERIMENTAL
Intervention: CEA assay with levels above 9 ng/ml
Number of subjects: 377

Group type: COMPARATOR
Intervention: CEA assay with levels less than 9 ng/ml
Number of subjects: 377

Group type: COMPARATOR
Intervention: Radionuclide liver scan
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: CEA assay
Number of subjects: 377
Study: 30561287

Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers (UCT) of 10,000 XOF monthly from July to November 2013 and 2014
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Control group (no cash transfers)
Number of subjects: 1143
Study: 27473182

Group type: EXPERIMENTAL
Intervention: Supplemental in-person EQUIP training with active feedback at 5 sites
Number of subjects: 22316

Group type: COMPARATOR
Intervention: Control sites (4 sites) without training or feedback
Number of subjects: 22316
Study: 26090428

Group type: EXPERIMENTAL
Intervention: 7-day nonbismuth containing quadruple therapy (EACM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 7-day standard triple therapy (EAC)
Number of subjects: 200
Study: 24267042

Group type: EXPERIMENTAL
Intervention: Soy protein (18 g/d) and isoflavone tablets (105 mg/d isoflavone aglycone equivalents)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Soy protein and placebo tablets
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Control protein and isoflavone tablets
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control protein and placebo tablets
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Equol producers
Number of subjects: 131
Study: 21787431

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) combined with medication (CBT/MED)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) combined with medication (TAU/MED)
Number of subjects: 54
Study: 19347683

Group type: EXPERIMENTAL
Intervention: Dementia care consultation intervention provided by dementia care consultants at an Alzheimer's association chapter over a 12-month period
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dementia care consultation intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group receiving educational and community resource information without care consultation
Number of subjects: 84
Study: 17943674

Group type: EXPERIMENTAL
Intervention: Vacuum-compression therapy (VCT) in addition to conventional therapy for 10 sessions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of VCT with conventional therapy
Number of subjects: 18
Study: 15476447

Group type: EXPERIMENTAL
Intervention: 131I plus pretreatment with methimazole (30 mg/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 131I alone
Number of subjects: 61
Study: 11546896

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging in CADASIL patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diffusion tensor imaging in controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation analysis in CADASIL patients
Number of subjects: 20
Study: 9602987

Group type: EXPERIMENTAL
Intervention: Intravesicular solution of 1.50 mg PGE2 (2 x 0.75 mg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No prophylaxis for urinary retention (Control)
Number of subjects: 110
Study: 7802235

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study: 3341246

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement for 3 months
Number of subjects: 0
Study: 31432392

Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole 300 mg (fasted)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral posaconazole 300 mg (fasted)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral posaconazole 300 mg (high-fat breakfast)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adverse events for intravenous posaconazole 300 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adverse events for oral posaconazole 300 mg (high-fat breakfast)
Number of subjects: 18
Study: 28592386

Group type: EXPERIMENTAL
Intervention: CT-P6
Number of subjects: 549

Group type: COMPARATOR
Intervention: Reference trastuzumab
Number of subjects: 549
Study: 26072311

Group type: EXPERIMENTAL
Intervention: Adherence therapy (AT) plus usual care
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual psychiatric care
Number of subjects: 114
Study: 23452682

Group type: EXPERIMENTAL
Intervention: Randomly assigned 14-month treatments for ADHD (specific treatments not detailed in the abstract)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Medication at follow-up (mostly stimulants)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Cumulative stimulant treatment over time
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: ADHD sample
Number of subjects: 436

Group type: COMPARATOR
Intervention: Non-ADHD sample
Number of subjects: 436
Study: 22035534

Group type: EXPERIMENTAL
Intervention: Control Preferences Scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared decision making
Number of subjects: 0
Study: 19745648

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa (black cohosh) extract
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17261982

Group type: EXPERIMENTAL
Intervention: Intubation period > 24 hrs (group I)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Intubation period < 24 hrs (group II)
Number of subjects: 237
Study: 14500073

Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microg/kg per min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 26
Study: 10718230

Group type: EXPERIMENTAL
Intervention: Nurse requested x rays
Number of subjects: 675

Group type: COMPARATOR
Intervention: Control group (doctors or ENPs requesting x rays)
Number of subjects: 675
Study: 9379368

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 40

Group type: COMPARATOR
Intervention: ECCE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 1316885

Group type: EXPERIMENTAL
Intervention: Cardiovasoprotective (CVP) diet (group A)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Normal diet (group B)
Number of subjects: 621
Study: 3707286

Group type: EXPERIMENTAL
Intervention: Diazepam (5 or 10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphetamine (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective effects of diazepam
Number of subjects: 0
Study: 29433506

Group type: EXPERIMENTAL
Intervention: Intervention arm with access to the app plus intervention messages
Number of subjects: 573

Group type: COMPARATOR
Intervention: Control arm with access to the app plus control messages
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 573
Study: 25567541

Group type: EXPERIMENTAL
Intervention: Ultracongruent (UC) TKA
Number of subjects: 90

Group type: COMPARATOR
Intervention: Posterior stabilized (PS) TKA
Number of subjects: 90
Study: 24919727

Group type: EXPERIMENTAL
Intervention: Mannitol 1g/kg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 53
Study: 22302818

Group type: EXPERIMENTAL
Intervention: Isochronous auditory rhythm
Number of subjects: 12
Study: 20108040

Group type: EXPERIMENTAL
Intervention: Resistin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IL-18
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) correlation with resistin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) correlation with IL-18
Number of subjects: 32
Study: 19065416

Group type: EXPERIMENTAL
Intervention: Cannula method (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Smith and Nozik method (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Orbital floor injection method (group 3)
Number of subjects: 30
Study: 16048152

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (0.2 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 23
Study: 12525336

Group type: EXPERIMENTAL
Intervention: Unsatisfactory primary care (less than 60% compliance to recommendations)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Unsatisfactory primary care
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Less than 2 visits to family physician during the last year
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Glucose level
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Cognitive level
Number of subjects: 258
Study: 10584045

Group type: EXPERIMENTAL
Intervention: High-MUFA diets (olive oil, peanut oil, peanuts and peanut butter)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Step II diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-MUFA diets
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-MUFA diets (OO, PO, PPB)
Number of subjects: 22
Study: 8714171

Group type: EXPERIMENTAL
Intervention: High doses of intravenous piracetam (12 g in 250 ml of saline)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1825100

Group type: EXPERIMENTAL
Intervention: AA-2414 (40 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AA-2414 (20 mg/day)
Number of subjects: 15
Study: 7028822

Group type: EXPERIMENTAL
Intervention: Dispersalloy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oraloy, Sybraloy, Tytin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aristaloy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispersalloy, Sybraloy
Number of subjects: 0
Study: 30012907

Group type: EXPERIMENTAL
Intervention: Dyslipidemia assessment through biochemical tests
Number of subjects: 2184
Study: 29896813

Group type: EXPERIMENTAL
Intervention: Respirator Intervention Phase (RIP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Headphone Intervention Phase (HIP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Respirator plus Headphone Intervention Phase (RHIP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Intervention Phase (NIP)
Number of subjects: 40
Study: 27289122

Group type: EXPERIMENTAL
Intervention: Intensive glycemic treatment
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Standard glycemic treatment
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1310
Study: 25196855

Group type: EXPERIMENTAL
Intervention: Combination treatments
Number of subjects: 961

Group type: COMPARATOR
Intervention: Non-complete remission (CR) status at HSCT
Number of subjects: 961

Group type: COMPARATOR
Intervention: Non-chronic graft-versus-host disease after HSCT
Number of subjects: 961

Group type: COMPARATOR
Intervention: Multifocal involvement at EMR
Number of subjects: 961

Group type: COMPARATOR
Intervention: Non-CR after EMR treatments
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Graft-versus-leukemia effect
Number of subjects: 961
Study: 22089534

Group type: EXPERIMENTAL
Intervention: Amlodipine alone
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: β-blocker
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor/angiotensin II receptor antagonist
Number of subjects: 279
Study: 20435205

Group type: COMPARATOR
Intervention: Simvastatin (20 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg) plus Ezetimibe (10 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 17368974

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestrogen only treatment
Number of subjects: 0
Study: 15755281

Group type: EXPERIMENTAL
Intervention: Ex vivo chemosensitivity testing using the chemosensitivity index (C(i))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemosensitivity index (C(i))
Number of subjects: 0
Study: 12072679

Group type: EXPERIMENTAL
Intervention: Liberal catheter replacement when clinically indicated (group II)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Routine catheter replacement every 5 days (group I)
Number of subjects: 43
Study: 10485423

Group type: EXPERIMENTAL
Intervention: Synthetic protein treated oxygenators
Number of subjects: 58

Group type: COMPARATOR
Intervention: Heparin coated circuits
Number of subjects: 58
Study: 8636371

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 300 mg/week
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 300 mg/week
Number of subjects: 11
Study: 1780961

Group type: EXPERIMENTAL
Intervention: Fasted (F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard Breakfast (SB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bolus of Enteral Nutrients (EB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Slow Infusion of Enteral Nutrients (EI)
Number of subjects: 8
Study: 7317698

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of cognitive therapy and antidepressants
Number of subjects: 64
Study: 31678438

Group type: EXPERIMENTAL
Intervention: Electronic Conductivity Device (ECD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional trocar
Number of subjects: 61
Study: 31621673

Group type: EXPERIMENTAL
Intervention: High thoracic epidural anesthesia
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mid thoracic epidural anesthesia
Number of subjects: 52
Study: 28483786

Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 689

Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 689
Study: 26100584

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 563
Study: 23411993

Group type: EXPERIMENTAL
Intervention: Emulsion eye drop (containing emulsified castor oil), dosed four times per day for 7 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Emulsion eye drop (containing emulsified castor oil)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dry eye subjects
Number of subjects: 20
Study: 22514897

Group type: EXPERIMENTAL
Intervention: Intramedullary nail with reaming (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramedullary nail without reaming (group B)
Number of subjects: 60
Study: 19176724

Group type: EXPERIMENTAL
Intervention: Variety of LED foods
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Variety of HED foods
Number of subjects: 84

Group type: COMPARATOR
Intervention: Same HED foods
Number of subjects: 84

Group type: COMPARATOR
Intervention: Same foods
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sensitized children
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Variety of foods
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: LED foods
Number of subjects: 84
Study: 17573736

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia in index pregnancy
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Gestational hypertension in index pregnancy
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Multiparous women with gestational hypertension
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Normal index pregnancy
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Hypertensive index pregnancy
Number of subjects: 1515
Study: 10971232

Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg twice daily
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 8795328

Group type: EXPERIMENTAL
Intervention: Topical lignocaine spray (40 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous lignocaine 0.5 mg.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous lignocaine 1.5 mg.kg‐1
Number of subjects: 90
Study: 1506123

Group type: EXPERIMENTAL
Intervention: Ibuprofen 5 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 6734051

Group type: EXPERIMENTAL
Intervention: Propranolol (0.05, 0.1, and 0.2 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil (0.1, 0.2, and 0.4 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 8
Study: 31490959

Group type: COMPARATOR
Intervention: LPV/r+3TC (dual therapy)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: LPV/r+2NRTIs (triple therapy)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Virologic suppression
Number of subjects: 172
Study: 29297472

Group type: EXPERIMENTAL
Intervention: Hybrid treatment (minimally invasive direct coronary artery bypass / percutaneous coronary intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Classic treatment (coronary artery bypass grafting / off‑pump coronary artery bypass)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hybrid treatment
Number of subjects: 200
Study: 27141838

Group type: EXPERIMENTAL
Intervention: Group 1 (larger LPPs to pleasant pictures)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group 2 (smaller LPPs to pleasant pictures)
Number of subjects: 45
Study: 24029429

Group type: EXPERIMENTAL
Intervention: Individualized dosing of ESA guided by the Smart Anemia Manager algorithm
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard protocol for ESA dosing
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Individualized dosing of ESA
Number of subjects: 62
Study: 22488277

Group type: EXPERIMENTAL
Intervention: Prefabricated, full‐length Quick Comfort Insoles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (athletic shoes without orthotics)
Number of subjects: 40
Study: 21313901

Group type: EXPERIMENTAL
Intervention: Citrullus colocynthis (300 mg daily for 6 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17512246

Group type: EXPERIMENTAL
Intervention: CPAP-pretreated group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-CPAP-pretreated group
Number of subjects: 140
Study: 16062095

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day and 100 mg/day
Number of subjects: 66
Study: 12185154

Group type: EXPERIMENTAL
Intervention: Home based care
Number of subjects: 201

Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 201
Study: 10420140

Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate
Number of subjects: 76

Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 76

Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 76
Study: 7486183

Group type: EXPERIMENTAL
Intervention: Methohexital (3.0 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Thiopental (7.3 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 1968484

Group type: EXPERIMENTAL
Intervention: Vancomycin (500 mg in 250 ml of 0.9% saline prior to catheter insertion and another 500 mg infused via the established catheter)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (0.9% saline alone, same regimen as vancomycin)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98